Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 31 | 2025 | 179 | 5.660 |
Why?
|
| Patient Readmission | 7 | 2025 | 122 | 4.470 |
Why?
|
| Breast Neoplasms | 21 | 2024 | 1723 | 4.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 220 | 2.790 |
Why?
|
| Budgets | 4 | 2025 | 15 | 2.420 |
Why?
|
| Decision Making | 9 | 2021 | 249 | 2.320 |
Why?
|
| Models, Economic | 11 | 2025 | 28 | 2.270 |
Why?
|
| Drug Costs | 8 | 2025 | 35 | 1.910 |
Why?
|
| Decision Support Techniques | 8 | 2024 | 49 | 1.790 |
Why?
|
| Delayed-Action Preparations | 2 | 2025 | 74 | 1.730 |
Why?
|
| Antipsychotic Agents | 2 | 2025 | 80 | 1.690 |
Why?
|
| Hospitalization | 6 | 2025 | 485 | 1.690 |
Why?
|
| Technology Assessment, Biomedical | 4 | 2025 | 12 | 1.670 |
Why?
|
| Delivery of Health Care | 8 | 2024 | 310 | 1.520 |
Why?
|
| Humans | 73 | 2025 | 43102 | 1.500 |
Why?
|
| United States | 30 | 2025 | 5205 | 1.490 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 83 | 1.390 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 749 | 1.350 |
Why?
|
| Female | 40 | 2025 | 24698 | 1.230 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2544 | 1.210 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 116 | 1.190 |
Why?
|
| Medicare | 10 | 2025 | 332 | 1.180 |
Why?
|
| Hospital Mortality | 2 | 2020 | 210 | 1.170 |
Why?
|
| Medication Adherence | 3 | 2025 | 182 | 0.990 |
Why?
|
| Aged | 21 | 2025 | 8214 | 0.980 |
Why?
|
| Alzheimer Disease | 2 | 2025 | 1001 | 0.980 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1019 | 0.950 |
Why?
|
| Risk Factors | 10 | 2025 | 3994 | 0.930 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2025 | 497 | 0.920 |
Why?
|
| Bibliometrics | 2 | 2024 | 16 | 0.900 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 195 | 0.850 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 25 | 0.840 |
Why?
|
| Schizophrenia | 1 | 2025 | 93 | 0.830 |
Why?
|
| Bipolar Disorder | 1 | 2025 | 84 | 0.830 |
Why?
|
| Adult | 19 | 2025 | 13872 | 0.800 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 47 | 0.800 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2022 | 75 | 0.790 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 163 | 0.720 |
Why?
|
| Critical Illness | 1 | 2022 | 47 | 0.720 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 432 | 0.710 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 9 | 0.700 |
Why?
|
| Middle Aged | 15 | 2025 | 12222 | 0.700 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 42 | 0.690 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 18 | 0.680 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 77 | 0.680 |
Why?
|
| Azithromycin | 1 | 2020 | 7 | 0.680 |
Why?
|
| Logistic Models | 4 | 2023 | 1009 | 0.660 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 42 | 0.650 |
Why?
|
| Frail Elderly | 1 | 2020 | 18 | 0.650 |
Why?
|
| Attitude to Death | 1 | 2020 | 23 | 0.650 |
Why?
|
| Antimalarials | 1 | 2020 | 64 | 0.640 |
Why?
|
| Markov Chains | 6 | 2020 | 43 | 0.640 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3156 | 0.630 |
Why?
|
| Length of Stay | 4 | 2023 | 229 | 0.630 |
Why?
|
| Databases, Factual | 4 | 2023 | 341 | 0.630 |
Why?
|
| Life Expectancy | 1 | 2020 | 72 | 0.620 |
Why?
|
| Immunotherapy | 1 | 2021 | 144 | 0.620 |
Why?
|
| Sirolimus | 3 | 2014 | 70 | 0.610 |
Why?
|
| Piperazines | 1 | 2020 | 120 | 0.610 |
Why?
|
| Pyridines | 1 | 2020 | 139 | 0.610 |
Why?
|
| Stroke | 2 | 2020 | 340 | 0.600 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 174 | 0.600 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 120 | 0.590 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 184 | 0.580 |
Why?
|
| Male | 17 | 2025 | 23409 | 0.580 |
Why?
|
| Brain Ischemia | 1 | 2020 | 189 | 0.560 |
Why?
|
| Longevity | 1 | 2020 | 173 | 0.560 |
Why?
|
| Treatment Outcome | 7 | 2020 | 1604 | 0.560 |
Why?
|
| Incretins | 1 | 2018 | 2 | 0.560 |
Why?
|
| Quality of Life | 3 | 2019 | 616 | 0.550 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 9 | 0.550 |
Why?
|
| Androstadienes | 2 | 2014 | 19 | 0.540 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 25 | 0.540 |
Why?
|
| Attitude to Health | 1 | 2020 | 338 | 0.530 |
Why?
|
| Health Care Costs | 4 | 2024 | 91 | 0.530 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 376 | 0.520 |
Why?
|
| Genetic Testing | 1 | 2018 | 91 | 0.520 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 237 | 0.510 |
Why?
|
| Drug Administration Schedule | 3 | 2025 | 153 | 0.500 |
Why?
|
| Risk Assessment | 4 | 2025 | 863 | 0.490 |
Why?
|
| Time Factors | 5 | 2021 | 1857 | 0.490 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2025 | 4 | 0.470 |
Why?
|
| Blood Glucose | 1 | 2018 | 389 | 0.470 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 2853 | 0.460 |
Why?
|
| Child | 6 | 2024 | 3443 | 0.450 |
Why?
|
| Hormones | 1 | 2015 | 55 | 0.450 |
Why?
|
| Injections | 2 | 2025 | 42 | 0.450 |
Why?
|
| Thiocarbamates | 1 | 2014 | 5 | 0.440 |
Why?
|
| Peptides | 1 | 2018 | 372 | 0.430 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2011 | 18 | 0.430 |
Why?
|
| Cost of Illness | 2 | 2025 | 98 | 0.420 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 11 | 0.420 |
Why?
|
| Economics, Medical | 1 | 2013 | 3 | 0.410 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 17 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 760 | 0.380 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 374 | 0.360 |
Why?
|
| Formularies as Topic | 1 | 2011 | 3 | 0.360 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 44 | 0.360 |
Why?
|
| Child, Preschool | 5 | 2024 | 1546 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 53 | 0.350 |
Why?
|
| Developing Countries | 1 | 2011 | 113 | 0.340 |
Why?
|
| Cote d'Ivoire | 3 | 2020 | 7 | 0.340 |
Why?
|
| Decision Trees | 3 | 2020 | 22 | 0.340 |
Why?
|
| Medical Oncology | 2 | 2025 | 50 | 0.330 |
Why?
|
| Prescription Drugs | 1 | 2011 | 32 | 0.330 |
Why?
|
| Young Adult | 7 | 2024 | 5080 | 0.310 |
Why?
|
| Melanoma | 2 | 2021 | 110 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 375 | 0.300 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 234 | 0.290 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 231 | 0.290 |
Why?
|
| Physicians | 1 | 2011 | 188 | 0.290 |
Why?
|
| Choice Behavior | 2 | 2021 | 93 | 0.280 |
Why?
|
| Norpregnenes | 1 | 2007 | 2 | 0.270 |
Why?
|
| Hot Flashes | 1 | 2007 | 8 | 0.270 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 19 | 0.270 |
Why?
|
| Adolescent | 5 | 2024 | 6081 | 0.270 |
Why?
|
| Disease Progression | 4 | 2025 | 667 | 0.270 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 42 | 0.270 |
Why?
|
| Taxoids | 2 | 2017 | 50 | 0.240 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 36 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 154 | 0.240 |
Why?
|
| Biomedical Technology | 1 | 2025 | 12 | 0.230 |
Why?
|
| Proteinuria | 1 | 2025 | 56 | 0.230 |
Why?
|
| Cost Savings | 1 | 2025 | 18 | 0.230 |
Why?
|
| Health Resources | 2 | 2016 | 37 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 64 | 0.220 |
Why?
|
| Teratogens | 1 | 2024 | 8 | 0.220 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2024 | 6 | 0.220 |
Why?
|
| Probability | 2 | 2016 | 82 | 0.220 |
Why?
|
| Costs and Cost Analysis | 1 | 2024 | 60 | 0.220 |
Why?
|
| Hepacivirus | 2 | 2022 | 74 | 0.220 |
Why?
|
| Health Care Sector | 1 | 2024 | 10 | 0.210 |
Why?
|
| Postmenopause | 2 | 2019 | 141 | 0.210 |
Why?
|
| Endrin | 1 | 2024 | 2 | 0.210 |
Why?
|
| Health Surveys | 1 | 2025 | 405 | 0.210 |
Why?
|
| Aortic Aneurysm | 1 | 2023 | 5 | 0.200 |
Why?
|
| Canada | 3 | 2016 | 163 | 0.200 |
Why?
|
| Drug Monitoring | 1 | 2024 | 69 | 0.200 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 830 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2024 | 145 | 0.200 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 278 | 0.200 |
Why?
|
| Antiviral Agents | 2 | 2022 | 195 | 0.190 |
Why?
|
| Drug Users | 1 | 2022 | 52 | 0.180 |
Why?
|
| Florida | 2 | 2021 | 478 | 0.180 |
Why?
|
| Propensity Score | 2 | 2023 | 59 | 0.180 |
Why?
|
| Sex Factors | 1 | 2025 | 1028 | 0.180 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 129 | 0.180 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 78 | 0.170 |
Why?
|
| Refuse Disposal | 1 | 2021 | 17 | 0.170 |
Why?
|
| Hospital Costs | 1 | 2021 | 27 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2022 | 139 | 0.170 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 2 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 6 | 0.170 |
Why?
|
| Patient Preference | 1 | 2021 | 60 | 0.170 |
Why?
|
| Papillomaviridae | 1 | 2022 | 142 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 29 | 0.170 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 15 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 23 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 5 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2020 | 21 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2022 | 1600 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2020 | 56 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 440 | 0.160 |
Why?
|
| Drugs, Generic | 1 | 2020 | 6 | 0.160 |
Why?
|
| Taiwan | 1 | 2019 | 23 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 27 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 89 | 0.160 |
Why?
|
| Cohort Studies | 2 | 2023 | 1759 | 0.160 |
Why?
|
| Survival Rate | 1 | 2020 | 355 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2020 | 185 | 0.150 |
Why?
|
| Vaccination | 1 | 2022 | 355 | 0.150 |
Why?
|
| Nitriles | 1 | 2019 | 81 | 0.150 |
Why?
|
| Quinolines | 1 | 2020 | 78 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2020 | 408 | 0.150 |
Why?
|
| Triazoles | 1 | 2019 | 102 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2020 | 122 | 0.150 |
Why?
|
| Monte Carlo Method | 2 | 2016 | 64 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2021 | 169 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 140 | 0.140 |
Why?
|
| Hypertension | 1 | 2025 | 835 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 133 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 122 | 0.140 |
Why?
|
| Ticlopidine | 1 | 2018 | 17 | 0.140 |
Why?
|
| Maytansine | 1 | 2017 | 2 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 368 | 0.140 |
Why?
|
| Adenosine | 1 | 2018 | 62 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 40 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 24 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 17 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 49 | 0.130 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 486 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2016 | 24 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 539 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 173 | 0.120 |
Why?
|
| Mexico | 1 | 2017 | 298 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2018 | 359 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 1175 | 0.120 |
Why?
|
| Prevalence | 1 | 2020 | 1612 | 0.120 |
Why?
|
| Vinblastine | 1 | 2015 | 9 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2015 | 17 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 27 | 0.110 |
Why?
|
| Accidental Falls | 1 | 2015 | 33 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 495 | 0.110 |
Why?
|
| Age Factors | 1 | 2018 | 1154 | 0.110 |
Why?
|
| Decision Making, Organizational | 1 | 2014 | 6 | 0.110 |
Why?
|
| Neoplasms | 1 | 2025 | 1377 | 0.110 |
Why?
|
| Health Records, Personal | 1 | 2014 | 6 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 70 | 0.110 |
Why?
|
| Incidence | 3 | 2024 | 1078 | 0.100 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 92 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 719 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 183 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2013 | 232 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 259 | 0.090 |
Why?
|
| Health Priorities | 1 | 2011 | 25 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2024 | 260 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 20 | 0.080 |
Why?
|
| Algorithms | 1 | 2014 | 509 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 259 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2024 | 972 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 291 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2018 | 2157 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 706 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 11 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 12 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 147 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 34 | 0.060 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2024 | 8 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 60 | 0.050 |
Why?
|
| Prescriptions | 1 | 2024 | 19 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2023 | 9 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 14 | 0.050 |
Why?
|
| SEER Program | 1 | 2024 | 164 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 65 | 0.050 |
Why?
|
| Survivors | 1 | 2024 | 152 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 32 | 0.050 |
Why?
|
| Glucosides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 50 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 37 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 252 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 246 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 48 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 103 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 4 | 0.040 |
Why?
|
| Palliative Care | 1 | 2020 | 61 | 0.040 |
Why?
|
| Aspirin | 1 | 2020 | 89 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1772 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 178 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 385 | 0.030 |
Why?
|
| Hippocampus | 1 | 2020 | 594 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 17 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 712 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 49 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 863 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 75 | 0.030 |
Why?
|
| Insulin | 1 | 2016 | 258 | 0.030 |
Why?
|